PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25261710-1	2014	Oral absorption of lopinavir (LPV) is limited due to P-glycoprotein (P-gp) and multidrug resistance-associated protein2 (MRP2) mediated efflux by intestinal epithelial cells.	Lopinavir	19-28	PGP	Canis lupus familiaris	53-67	
25261710-1	2014	Oral absorption of lopinavir (LPV) is limited due to P-glycoprotein (P-gp) and multidrug resistance-associated protein2 (MRP2) mediated efflux by intestinal epithelial cells.	Lopinavir	19-28	PGP	Canis lupus familiaris	69-73	
25261710-1	2014	Oral absorption of lopinavir (LPV) is limited due to P-glycoprotein (P-gp) and multidrug resistance-associated protein2 (MRP2) mediated efflux by intestinal epithelial cells.	Lopinavir	30-33	PGP	Canis lupus familiaris	53-67	
25261710-1	2014	Oral absorption of lopinavir (LPV) is limited due to P-glycoprotein (P-gp) and multidrug resistance-associated protein2 (MRP2) mediated efflux by intestinal epithelial cells.	Lopinavir	30-33	PGP	Canis lupus familiaris	69-73	
25261710-3	2014	In the present study, dipeptide prodrug approach was employed to circumvent efflux pumps (P-gp and MRP2) and CYP3A4 mediated metabolism of LPV.	Lopinavir	139-142	PGP	Canis lupus familiaris	90-94	
17664327-8	2007	Pgp inhibition constants ranged from 10.3 microM (lopinavir) to >100 microM (amprenavir, indinavir, and darunavir).	Lopinavir	50-59	PGP	Canis lupus familiaris	0-3	
17451894-0	2007	Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor.	Lopinavir	40-49	PGP	Canis lupus familiaris	5-9